View Filing Data

Print Document View Excel Document

Document and Entity Information Document - shares	3 Months Ended
Document and Entity Information Document - shares	Mar. 31, 2015	May 04, 2015
Document Information [Line Items]
Entity Registrant Name	NeoStem, Inc.
Entity Central Index Key	0000320017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		40,151,373

Consolidated Balance Sheets - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 19,131,285	$ 19,174,061
Marketable securities	0	7,080,053
Accounts receivable, net of allowance for doubtful accounts of $383,490 and $385,362 at March 31, 2015 and December 31, 2014, respectively	1,968,790	3,111,274
Deferred costs	3,621,351	2,566,989
Prepaid expenses and other current assets	4,296,836	4,349,167
Total current assets	29,018,262	36,281,544
Property, plant and equipment, net	15,852,124	15,960,731
Goodwill	25,209,336	25,209,336
Intangible assets, net	47,409,104	47,560,406
Other assets	1,325,085	1,263,375
Total assets	118,813,911	126,275,392
Current Liabilities
Accounts payable	2,928,703	5,661,173
Accrued liabilities	5,723,787	4,322,901
Long-term debt, current	2,242,971	1,109,612
Notes payable	1,061,571	816,776
Unearned revenues	5,505,819	4,334,120
Total current liabilities	17,462,851	16,244,582
Long-term Liabilities
Deferred income taxes	18,222,823	18,176,190
Notes payable	662,294	825,897
Long-term debt	12,757,029	13,890,388
Acquisition-related contingent consideration	18,810,000	18,260,000
Other long-term liabilities	930,355	804,546
Total liabilities	68,845,352	68,201,603
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock liquidation value, 0.01 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2015 and December 31, 2014	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 39,423,911 and 36,783,857 shares, at March 31, 2015 and December 31, 2014, respectively	39,424	36,784
Additional paid-in capital	361,503,313	350,428,903
Treasury stock, at cost	(705,742)	(705,742)
Accumulated deficit	(310,433,434)	(291,246,538)
Accumulated other comprehensive income	0	1,329
Total NeoStem, Inc. stockholders' equity	50,403,661	58,514,836
Noncontrolling interests	(435,102)	(441,047)
Total equity	49,968,559	58,073,789
Liabilities and Equity, Total	$ 118,813,911	$ 126,275,392

Consolidated Balance Sheets (Parentheticals) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Preferred Stock, Shares Outstanding	10,000	10,000
Common Stock, Par Value	$ 0.001	$ 0.001
Accounts receivable trade, net of allowance for doubtful accounts	$ 383,490	$ 385,362
Preferred Stock, authorized	20,000,000	20,000,000
Common Stock, Shares, Outstanding	39,423,911	36,783,857
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	39,423,911	36,783,857
Preferred stock, shares designated	825,000	825,000
Preferred stock, issued	10,000	10,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock	0.01	0.01
Preferred stock, par value	$ 0.01	$ 0.01

Consolidated Statements of Operations - USD ($)	3 Months Ended
Consolidated Statements of Operations - USD ($)	Mar. 31, 2015	Mar. 31, 2014
Revenues	$ 3,172,279	$ 4,055,575
Cost of revenues	3,368,612	3,825,444
Research and development	6,803,632	4,759,083
Selling, general, and administrative	11,087,899	8,970,016
Total operating costs and expenses	21,260,143	17,554,543
Operating loss	(18,087,864)	(13,498,968)
Other expense:
Other expense, net	(546,027)	(189,551)
Interest expense	(550,964)	(94,156)
Nonoperating Income (Expense), Total	(1,096,991)	(283,707)
Loss before provision for income taxes and noncontrolling interests	(19,184,855)	(13,782,675)
Provision for income taxes	46,633	47,409
Net loss	(19,231,488)	(13,830,084)
Less - loss attributable to noncontrolling interests	(44,592)	(148,027)
Net loss attributable to NeoStem, Inc. common stockholders	$ (19,186,896)	$ (13,682,057)
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	$ (0.51)	$ (0.49)
Weighted average common shares outstanding	37,594,894	28,120,847

Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Mar. 31, 2015	Mar. 31, 2014
Net loss	$ (19,231,488)	$ (13,830,084)
Available for sale securities - net unrealized loss	(1,329)	0
Total other comprehensive loss	(1,329)	0
Comprehensive loss	(19,232,817)	(13,830,084)
Comprehensive loss attributable to noncontrolling interests	(44,592)	(148,027)
Comprehensive net loss attributable to NeoStem, Inc. common stockholders	$ (19,188,225)	$ (13,682,057)

Consolidated Statements of Equity - USD ($)	Total	Total NeoStem, Inc. Shareholders' Equity [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
Beginning Balance (shares) at Dec. 31, 2013			10,000	27,196,537
Beginning Balance at Dec. 31, 2013	$ 62,026,435	$ 62,542,475	$ 100	$ 27,197	$ 299,594,525	$ 0	$ (236,373,605)	$ (705,742)	$ (516,040)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(13,830,084)	(13,682,057)					(13,682,057)		(148,027)
Share-based compensation (in shares)				329,698
Share-based compensation	3,893,616	3,893,616		$ 330	3,893,286
Stock Issued During Period, Shares, New Issues				804,375
Net proceeds from issuance of common stock	5,630,625	5,630,625		$ 804	5,629,821
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				12,800
Proceeds from exercise of options	71,360	71,360		$ 13	71,347
Proceeds from warrant exercise (in shares)				250,000
Stock Issued During Period, Value, Warrant Exercises	1,275,000	1,275,000		$ 250	1,274,750
Change in Ownership in Subsidiary	0	(86,617)			(86,617)				86,617
Ending Balance at Mar. 31, 2014	59,066,952	59,644,402	$ 100	$ 28,594	310,377,112	0	(250,055,662)	(705,742)	(577,450)
Ending Balance (shares) at Mar. 31, 2014			10,000	28,593,410
Beginning Balance (shares) at Dec. 31, 2014			10,000	36,783,857
Beginning Balance at Dec. 31, 2014	58,073,789	58,514,836	$ 100	$ 36,784	350,428,903	1,329	(291,246,538)	(705,742)	(441,047)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(19,231,488)	(19,186,896)					(19,186,896)		(44,592)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	(1,329)	(1,329)				(1,329)
Share-based compensation (in shares)				470,289
Share-based compensation	3,715,759	3,715,759		$ 470	3,715,289
Stock Issued During Period, Shares, New Issues				2,169,765
Net proceeds from issuance of common stock	7,411,828	7,411,828		$ 2,170	7,409,658
Proceeds from exercise of options	0
Change in Ownership in Subsidiary	0	(50,537)			(50,537)				50,537
Ending Balance at Mar. 31, 2015	$ 49,968,559	$ 50,403,661	$ 100	$ 39,424	$ 361,503,313	$ 0	$ (310,433,434)	$ (705,742)	$ (435,102)
Ending Balance (shares) at Mar. 31, 2015			10,000	39,423,911

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	$ (19,231,488)	$ (13,830,084)
Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation expense	3,715,759	3,893,616
Depreciation and amortization	604,440	444,452
Change in acquisition-related contingent consideration	550,000	190,000
Bad debt recovery	(1,873)	(1,711)
Deferred income taxes	46,633	47,409
Accretion Expense	29,724	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	52,331	(271,149)
Accounts receivable	1,144,356	(25,012)
Deferred costs	(1,054,362)	(205,589)
Unearned revenues	1,171,699	216,515
Other assets	(61,711)	(53,035)
Accounts payable, accrued liabilities and other liabilities	(1,205,775)	(1,658,952)
Net cash used in operating activities	(14,240,267)	(11,253,540)
Cash flows from investing activities:
Proceeds from Sale and Maturity of Marketable Securities	7,049,000	0
Acquisition of property, plant and equipment	(344,530)	(1,239,606)
Net cash provided by (used in) investing activities	6,704,470	(1,239,606)
Cash flows from financing activities:
Proceeds from exercise of options	0	71,360
Proceeds from exercise of warrants	0	1,275,000
Net proceeds from issuance of common stock	7,411,828	5,630,625
Repayment of mortgage loan	0	(52,768)
Proceeds from notes payable	340,270	958,014
Repayment of notes payable	(259,077)	(163,192)
Net cash provided by financing activities	7,493,021	7,719,039
Net decrease in cash and cash equivalents	(42,776)	(4,774,107)
Cash and cash equivalents at beginning of period	19,174,061	46,133,759
Cash and cash equivalents at beginning of period	19,131,285	41,359,652
Cash paid during the period for:
Interest	$ 372,550	$ 93,100

The Business

3 Months Ended

Mar. 31, 2015

The Business [Abstract]

Nature of Operations [Text Block]

The Business

Overview

NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a vertically integrated, clinical-stage biopharmaceutical company that is pursuing the preservation and enhancement of human health through the development of individualized cell-based therapeutics that leverage the body’s natural ability to heal and fight disease. Our diversified pipeline and unique capabilities for innovative, cost-effective and efficient in-house development set us apart in this emerging industry as we work to fundamentally change the treatment paradigm for several serious diseases. In the coming weeks, NeoStem intends to change its corporate name and brand identity. The new corporate name is another step in the evolution of the Company, emphasizing our unique integrated approach to cell therapy and our therapeutic development focus on immune therapy.

Our most advanced clinical program is based on our dendritic cell/cancer cell technology. It is focused on the development of an innovative cancer treatment that is designed to target the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells (CICs), using purified CICs from a patient’s own tumor as an antigen source to induce or enhance an anti-tumor immune response in the patient. Our lead product candidate based on this platform technology, NBS20, targets malignant melanoma as an initial indication. NBS20 is being studied in patients with recurrent Stage III or Stage IV metastatic melanoma. The program has been granted Fast Track and Orphan designation by the Food and Drug Administration (FDA) as well as Advanced Therapeutic Medicinal Product classification by the European Medicines Agency (EMA). The protocol for the Phase 3 study, known as the Intus study, is the subject of a Special Protocol Assessment (SPA) by FDA. Our SPA letter states that our Phase 3 clinical trial is adequately designed to provide the necessary data that, depending on outcome, could support a Biologics License Application (BLA) seeking marketing approval of NBS20. This protocol calls for randomizing 250 patients. Patient screening began in the first quarter of 2015 and randomization of the first patient was announced in April 2015. Interim analysis of the data is targeted for the fourth quarter of 2017. We are also evaluating other clinical indications for which we may advance this program, including ovarian, liver, colon and lung cancers.

We are also developing therapies that are designed to utilize CD34 cells to regenerate tissue impacted by ischemia. Ischemia occurs when the supply of oxygenated blood in the body is restricted, causing local tissue distress and death. Results of ischemia include conditions such as acute myocardial infarction (heart attack) (AMI), chronic heart failure (CHF) and critical limb ischemia (CLI). We seek to improve oxygen delivery to affected tissues through the development and formation of new blood vessels. Initial investigations for this therapeutic platform have focused on NBS10, our most clinically advanced product candidate in our ischemic repair program. NBS10 is designed to prevent heart failure and major adverse cardiac events following a severe heart attack, known as an ST segment elevation myocardial infarction (STEMI). At the American Heart Association’s Scientific Sessions in November 2014, we reported six month data from the primary analysis of our 161 patient PreSERVE AMI study, and at the American College of Cardiology's 64th Annual Scientific Sessions and Expo in March 2015, we presented updated safety and exploratory efficacy results from the 12 month follow-up for the PreSERVE AMI trial. Our interim conclusions based on the six and twelve month results, which represent twelve and eighteen months median of patient follow-up respectively, are that (i) there is a CD34 does-dependent trend in reduction of major adverse cardiac events (MACE), including a signal for a mortality benefit based on the 12 month data; (ii) there is a signal for reduction in frequency in serious adverse events (SAEs) in higher dose groups based on the 12 month data; (iii) there is a CD34 cell dose-dependent trend in improvement of left ventricular ejection fraction and reduction in infarct size; and (iv) there is no correlation between experimental endpoint of perfusion and treatment.

We expect to complete the PreSERVE AMI study as defined through the final three-year follow-up and, in the meantime, plan to refine our development plan in consultation with our medical advisory board and relevant authorities in the second half of 2015. We also are evaluating other clinical indications that involve ischemia into which we may advance this program, including CLI and CHF.

We are also developing a therapy that is designed to utilize Regulatory T Cells (Tregs) to treat diseases caused by imbalances in an individual's immune system. This novel approach seeks to restore immune balance by enhancing Treg cell number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and other foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease, it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues. We have received a letter from the FDA stating that we may proceed on a Phase 2 study of NBS03D, a Treg based therapeutic being developed to treat type 1 diabetes mellitus (T1DM) in adolescents, and we plan to initiate the trial in late 2015 or 2016 depending on resource availability. We are evaluating other clinical indications into which we may advance this program, including steroid resistant asthma, multiple sclerosis, chronic obstructive pulmonary disease, inflammatory bowel disease, graft versus host disease, lupus, and rheumatoid arthritis.

Finally, we are actively exploring means to facilitate development in Japan, including filing an IND in Japan for one or more programs under Japan’s regenerative medicine law. Japan’s regenerative medicine law enables an expedited path to conditional approval for regenerative medicine products that show sufficient safety evidence and signals of efficacy. Potential indications for this unique opportunity include, among others, our immune-oncology program in liver cancer and our ischemic repair program in CLI.

We believe that cell-based therapies have the potential to create a paradigm change in the treatment for a variety of diseases and conditions and we are evaluating other programs that we view as holding particular promise, including an aesthetics program for a topical skin application and a very small embryonic like (VSEL^TM) stem cell program for the treatment of retinal degeneration, bone restoration and wound healing.

Through our wholly owned subsidiary, Progenitor Cell Therapy, LLC ( PCT), we are recognized as a world industry leader in providing high quality innovative and reliable manufacturing capabilities and engineering solutions (e.g., process development) in the development of cell-based therapies. We currently operate three facilities qualified under Good Manufacturing Practices (cGMPs) in Allendale, NJ, Mountain View, CA and Irvine, CA, and are poised to expand our facilities internationally. In addition to leveraging this core expertise in the development of our own products, we partner opportunistically with other industry leaders who recognize our unique ability to significantly improve their manufacturing processes and supply clinical and commercial material.

We look forward to further advancement of our cell-based therapies to the market and to helping patients suffering from life-threatening medical conditions. Coupling our development expertise with our strong process development and manufacturing capability, we believe the stage is set for us to realize meaningful clinical development of our own proprietary platform technologies and manufacturing advancements, further positioning NeoStem as a leader in the cell therapy industry.

We anticipate requiring additional capital in order to fund the development of cell therapy product candidates and to grow the PCT business. To meet our short and long term liquidity needs, we currently expect to use existing cash and cash equivalents balances, our revenue generating activities, and a variety of other means, including the continued use of a common stock purchase agreement with Aspire Capital (see Note 15). Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, additional warrant exercises, option exercises, partnerships and/or collaborations, and/or sale of assets. In addition, we will continue to seek as appropriate grants for scientific and clinical studies from various governmental agencies and foundations. We believe that our current cash, cash equivalents and marketable securities balances and revenue generating activities, along with access to funds under our agreement with Aspire Capital, will be sufficient to fund the business through the next 12 months. While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay or discontinue the acquisition and development of cell therapies, and/or the expansion of our business or raise funds on terms that we currently consider unfavorable.

Basis of Presentation

The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of March 31, 2015 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2014, 2013 and 2012 included in our Annual Report on Form 10-K for the year ended December 31, 2014. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining the fair values of goodwill for potential goodwill impairments for our reporting units, fair values of In-Process R&D assets, fair values of acquisition-related contingent considerations, useful lives of our tangible and intangible assets, allowances for doubtful accounts, and stock-based awards values. Accordingly, actual results could differ from those estimates and assumptions.

An accounting policy is considered to be critical if it is important to the Company’s financial condition and results of operations and if it requires management’s most difficult, subjective and complex judgments in its application.

Reclassifications

Certain reclassifications have been made to the Consolidated Financial Statements and Notes to the Consolidated Financial Statements for the three months ended March 31, 2014 to conform to the presentation for the three months ended March 31, 2015.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of NeoStem, Inc. and its wholly-owned and partially-owned subsidiaries and affiliates as listed below.



Entity	Percentage of Ownership	Location
NeoStem, Inc.	100%	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	96.6%	United States of America
PCT Allendale, LLC	100%	United States of America
NeoStem Oncology, LLC	100%	United States of America

(1) As of March 31, 2015, Becton Dickinson's ownership interest in Athelos was 3.4%.

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2015

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies [Text Block]

Summary of Significant Accounting Policies

In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our 2014 Form 10-K. There were no changes during the three months ended March 31, 2015.

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of 90 days or less when purchased.

Marketable Securities

The Company determines the appropriate classification of our marketable securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in either cash equivalents or marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline.

Accounts Receivable

Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.

Deferred Costs

The Company, through its PCT subsidiary, regularly enters into contracts with clients for services that have multiple stages and are dependent on one another to complete the contract and recognize revenue. The Company's inventory primarily represents work in process for costs incurred on such projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.

Share-Based Compensation

The Company expenses all share-based payment awards to employees, directors, advisors and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Advisor and consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Goodwill and Indefinite-Lived Intangible Assets

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in process research and development (IPR&D) programs acquired in the acquisitions of Amorcyte, LLC (the "Amorcyte Acquisition") and California Stem Cell, Inc. (CSC), as the Company expects future research and development on these programs to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.

The Company reviews goodwill and indefinite-lived intangible assets at least annually, or at the time a triggering event is identified for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit or the IPR&D below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing an income approach model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s and IPR&D's estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. In accordance with its accounting policy, the Company tested goodwill for impairment as of December 31, 2014, 2013, and 2012 for its two reporting units as well as its IPR&D, and concluded there was no goodwill and IPR&D impairment. No triggering events were noted in the current period that would require interim impairment assessment.

Definite-Lived Intangible Assets

Definite-lived intangible assets consist of customer lists, manufacturing technology, tradenames, patents and rights. These intangible assets are amortized on a straight line basis over their respective useful lives. The Company reviews definite-lived intangibles assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. No triggering events were noted in the current period that would require interim impairment assessment.

Recognizing and Measuring Assets Acquired and Liabilities Assumed in Business Combinations at Fair Value

The Company accounts for acquired businesses using the purchase method of accounting, which requires that assets acquired and liabilities assumed be recorded at date of acquisition at their respective fair values. The consolidated financial statements and results of operations reflect an acquired business after the completion of the acquisition. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to IPR&D are included on the balance sheet. Intangible assets, including IPR&D assets upon successful completion of the project and approval of the product, are amortized on a straight-line basis to amortization expense over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to present value expected from future net cash flow streams, the timing of approvals for IPR&D projects and the timing of related product launch dates, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the resulting timing and amount charged to, or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results.

The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates, post-tax gross profit levels and a probability assessment with respect to the likelihood of achieving contingent obligations including contingent payments such as milestone obligations, royalty obligations and contract earn-out criteria, where applicable. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting. The resulting probability-weighted cash flows are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value at that time and changes in fair value will be reflected as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Changes in assumptions utilized in our contingent consideration fair value estimates could result in an increase or decrease in our contingent consideration obligation and a corresponding charge to operating loss or gain.

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.

We recognize revenues when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.

Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. Progress billings collected prior to contract completion are recorded as unearned revenue until such time the contract is completed, which usually requires formal client acceptance.

Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.

Some client agreements include multiple elements, comprised of process development and clinical manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. The Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.

Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended March 31, 2015 and 2014, clinical services reimbursements were $0.5 million and $0.7 million, respectively.

Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of autologous adult stem cells when the cryopreservation process is completed which is approximately 24 hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

Recently Issued Accounting Pronouncement

In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)." The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2016 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements - Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the provisions in this ASU should be followed to determine whether to disclose information about the relevant conditions and events. The ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the adoption of this ASU and its impact on the consolidated financial statements.

Acquisition

3 Months Ended

Mar. 31, 2015

Business Combinations [Abstract]

Mergers, Acquisitions and Dispositions Disclosures [Text Block]

Acquisition

On May 8, 2014, NeoStem closed (the “Closing”) its acquisition of CSC (the “CSC Acquisition”), pursuant to the terms of the Agreement and Plan of Merger, dated as of April 11, 2014 (the “Merger Agreement”), by and among NeoStem and its acquisition subsidiaries (collectively, "Subco"), CSC and Jason Livingston, solely in his capacity as CSC stockholder representative (together with his permitted successors, the “CSC Representative”). At Closing, Fortis Advisors LLC succeeded to the duties of the CSC Representative pursuant to the Merger Agreement. Pursuant to the Merger Agreement, on the Closing date, Subco was merged with CSC (the “Merger”), with Subco surviving the Merger as a wholly-owned subsidiary of NeoStem. At Closing, Subco changed its legal name to NeoStem Oncology, LLC.

Aggregate Merger Consideration

Pursuant to the terms of the Merger Agreement, all shares of CSC common stock (“CSC Common Stock”) and CSC preferred stock (“CSC Preferred Stock”, and collectively with the CSC Common Stock, the “CSC Capital Stock”) outstanding immediately prior to the Closing, and all outstanding unexercised options to purchase CSC Common Stock (“CSC Options”) (treated as if a net exercise had occurred), were canceled and converted into the right to receive, in the aggregate (and giving effect to the liquidation preferences accorded to the CSC Preferred Stock):

(1)An aggregate of 5,329,593 shares of NeoStem common stock (subject to payment of nominal cash in lieu of fractional shares) (the “Closing Merger Consideration”).

(2)if payable after the Closing, certain payments in an amount of up to $90.0 million in the aggregate, payable in shares of NeoStem common stock or cash, in NeoStem’s sole discretion, in the event of the successful completion of certain milestone events in connection with the CSC Acquisition (the “Milestone Payments”, and together with the Closing Merger Consideration, the “Merger Consideration”).

The fair value of the net assets acquired in the CSC Acquisition was $19.4 million. The fair value of the consideration paid by NeoStem was valued at $33.5 million, resulting in the recognition of goodwill in the amount of $14.1 million. The consideration paid was comprised of equity issued and milestone payments. The fair value of the equity issued by NeoStem was valued at $21.6 million. The fair value of the milestone payments was valued at $11.9 million, and is contingent on the achievement of certain milestones associated with the future development of the acquired programs. Such contingent consideration has been classified as a liability and will be subject to remeasurement at the end of each reporting period.

The preliminary fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):



Cash and cash equivalents	$	51
Accounts receivable trade, net	45
Prepaids and other current assets	19
Property, plant and equipment, net	1,041
Other assets	201
Goodwill	14,092
In-Process R&D	34,290
Accounts payable	(333		)
Accrued liabilities	(2,014		)
Deferred tax liability	(13,901		)
Total	$	33,491

The total cost of the acquisition, which is still preliminary, has been allocated to the assets acquired and the liabilities assumed based upon their estimated fair values at the date of the acquisition. The final allocation is expected to be completed during the measurement period which is one year from the date of acquisition.

Pro Forma Financial Information

The following supplemental table presents unaudited consolidated pro forma financial information as if the closing of the CSC Acquisition had occurred on January 1, 2014 (in thousands, except per share amounts):



	Three Months Ended March 31, 2014
	(As Reported)			(Proforma)
Revenues	$	4,056		$	4,272
Net loss	$	(13,830	)	$	(15,523	)
Net loss attributable to NeoStem	$	(13,682	)	$	(15,375	)
Net loss per share attributable to NeoStem	$	(0.49	)	$	(0.46	)

The unaudited supplemental pro forma financial information should not be considered indicative of the results that would have occurred if the CSC Acquisition had been consummated on January 1, 2014, nor are they indicative of future results.

Available-for-Sale-Securities (Notes)

3 Months Ended

Mar. 31, 2015

Available-for-sale Securities [Abstract]

Cash, Cash Equivalents, and Marketable Securities [Text Block]

Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	March 31, 2015
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Money market funds	$	14,513.1	$	—	$	—	$	14,513.1
Total	$	14,513.1	$	—	$	—	$	14,513.1

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):



	March 31, 2015
Cash and cash equivalents	$	14,513.1
Marketable securities	—
Total	$	14,513.1

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	March 31, 2015
	Amortized Cost		Estimated Fair Value
Less than one year	$	14,513.1	$	14,513.1
Greater than one year	—		—
Total	$	14,513.1	$	14,513.1

Deferred Costs	3 Months Ended
Deferred Costs	Mar. 31, 2015
Inventories [Abstract]
Deferred Costs	Deferred costs, representing work in process for costs incurred on process development contracts that have not been completed, were $3.6 million and $2.6 million as of March 31, 2015 and December 31, 2014, respectively. The Company also has deferred revenue of approximately $5.1 million and $3.9 million of advance billings received as of March 31, 2015 and December 31, 2014, respectively, related to these contracts.

Loss Per Share

3 Months Ended

Mar. 31, 2015

Loss Per Share [Abstract]

Loss Per Share [Text Block]

Loss Per Share

For the three months ended March 31, 2015 and 2014, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive. At March 31, 2015 and 2014, the Company excluded the following potentially dilutive securities:



	March 31,
	2015	2014
Stock Options	6,371,533	3,912,697
Warrants	3,545,756	4,491,028
Restricted Shares	218,229	175,731

Fair Value Measurements

3 Months Ended

Mar. 31, 2015

Fair Value Measurements [Abstract]

Fair Value Disclosures [Text Block]

Fair Value Measurements

The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The Company classifies the fair value of the warrant derivative liabilities as Level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows. In May 2014, the warrants expired and the value of the warrant derivative liabilities were written off and recorded in other expenses in our consolidated statement of operations.

The Company classifies the fair value of contingent consideration obligations as Level 3 inputs. The Company has recognized contingent consideration obligations related to the following:

•

In October 2011, in connection with the Amorcyte Acquisition, contingent consideration obligations were recognized relating to earn out payments equal to 10% of the net sales of the lead product candidate NBS10 (in the event of and following the date of first commercial sale of NBS10), provided that in the event NeoStem sublicenses NBS10, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that NeoStem will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”). The contingent consideration fair value increased from $5.5 million as of December 31, 2014 to $5.6 million as of March 31, 2015. The change in estimated fair value is based on the impact of the time progression through the PreSERVE AMI Phase 2 clinical trial from December 31, 2014 to March 31, 2015, and has been recorded in other expenses in our consolidated statement of operations.

•

In May 2014, in connection with the CSC Acquisition, contingent consideration obligations were recognized relating to milestone payments of up to $90.0 million, based on the achievement of certain milestones associated with the future development of the acquired programs. The contingent consideration fair value increased from $12.8 million as of December 31, 2014 to $13.2 million as of March 31, 2015. The change in estimated fair value is based on the impact of the time progression to reach those milestones as of March 31, 2015, and has been recorded in other expenses in our consolidated statement of operations.

The fair value of contingent consideration obligations is based on discounted cash flow models using a probability-weighted income approach. The measurements are based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The Company bases the timing to complete the development and approval programs on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2015, and December 31, 2014 (in thousands):



	March 31, 2015								December 31, 2014
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	—	$	—	$	—	$	—	$	7,080.0	$	—	$	7,080.0
	$	—	$	—	$	—	$	—	$	—	$	7,080.0	$	—	$	7,080.0

Liabilities:
Contingent consideration	$	—	$	—	$	18,810.0	$	18,810.0	$	—	$	—	$	18,260.0	$	18,260.0
	$	—	$	—	$	18,810.0	$	18,810.0	$	—	$	—	$	18,260.0	$	18,260.0

There were no transfers of financial instruments to or from Levels 1, 2 or 3 during the periods presented. For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three months ended March 31, 2015 by type of instrument (in thousands):



	Three Months Ended
	March 31, 2015
	Contingent Consideration		Total
Beginning liability balance	$	18,260.0	$	18,260.0
Change in fair value recorded in operations	550.0		550.0
Ending liability balance	$	18,810.0	$	18,810.0

Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, and accounts payable. Our long-term debt and notes payable are carried at cost and approximate fair value due to their variable or fixed interest rates, which are consistent with the interest rates in the market.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Goodwill and Other Intangible Assets

3 Months Ended

Mar. 31, 2015

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Intangible Assets [Text Block]

Goodwill and Other Intangible Assets

The Company's goodwill was $25.2 million as of March 31, 2015 and December 31, 2014.

The Company's intangible assets and related accumulated amortization as of March 31, 2015 and December 31, 2014 consisted of the following (in thousands):



		March 31, 2015							December 31, 2014
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(420.1	)	$	579.9	$	1,000.0	$	(395.1	)	$	604.9
Manufacturing technology	10 years	3,900.0		(1,638.4		)	2,261.6		3,900.0		(1,540.9		)	2,359.1
Tradename	10 years	800.0		(336.1		)	463.9		800.0		(316.1		)	483.9
In process R&D	Indefinite	43,690.0		—			43,690.0		43,690.0		—			43,690.0
Patent rights	19 years	669.0		(255.3		)	413.7		669.0		(246.5		)	422.5
Total Intangible Assets		$	50,059.0	$	(2,649.9	)	$	47,409.1	$	50,059.0	$	(2,498.6	)	$	47,560.4

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Three Months Ended March 31,
	2015		2014
Cost of revenue	$	79.2	$	79.2
Research and development	27.1		27.1
Selling, general and administrative	45.0		45.0
Total	$	151.3	$	151.3

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2015	$	453.9
2016	605.2
2017	605.2
2018	605.2
2019	605.2
Thereafter	44,534.4
Total	$	47,409.1

Accrued Liabilities

3 Months Ended

Mar. 31, 2015

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities

Accrued liabilities as of March 31, 2015 and December 31, 2014 were as follows (in thousands):



	March 31, 2015		December 31, 2014
Salaries, employee benefits and related taxes	$	3,335.9	$	2,807.2
Professional fees	463.6		495.4
Other	1,924.3		1,020.3
Total	$	5,723.8	$	4,322.9

Debt

3 Months Ended

Mar. 31, 2015

Debt [Abstract]

Debt Disclosure [Text Block]

Debt

Notes Payable

As of March 31, 2015 and December 31, 2014, the Company had notes payable of approximately $1.7 million and $1.6 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.

Long-Term Debt

On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender has agreed to lend the Company up to $20.0 million. Upon entering into the Loan and Security Agreement, the Lender disbursed $15.0 million (“Term Loan A”). Under the terms of the Loan and Security Agreement, during the Second Draw Period (as defined below), the Company may, subject to certain conditions, borrow from Lender an additional $5.0 million (“Term Loan B”, together with Term Loan A, the “Term Loans”). The “Second Draw Period” is the period of time: (a) commencing on the date that Lender receives evidence in a form and substance satisfactory to Lender that the Company has entered into a strategic arrangement with respect to the Company’s NBS10 product candidate for ST Elevation Myocardial Infarction and receives an upfront payment of not less than $10.0 million in connection therewith, and (b) ending on the earlier of September 19, 2015 or the occurrence of an event of default under the Term Loans. After repayment of all outstanding amounts due under two loans from TD Bank, N.A. in the amount of approximately $3.1 million, and deductions for debt offering/issuance costs and interim period interest, the net proceeds from Term Loan A were $11.7 million. The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Term Loans using the effective interest rate method. The proceeds from the Term Loans may be used to satisfy the Company’s future working capital needs, including the development of its cell therapy product candidates.

The Company will make interest-only payments on the outstanding amount of Term Loans on a monthly basis until October 1, 2015 at a rate of 8.50% per annum; provided however, such interest-only period may be extended to April 1, 2016, in the event of either (1) the signing of a partnership for (x) traumatic brain injury indication for the Company's Ischemic Repair Program or for its VSEL^TM Program or (y) critical limb ischemia indication for its Ischemic Repair Program; or (2) the initiation of the Intus Phase 3 study evaluating the Company's product candidate NBS20 (also referred to as DC/TC) in patients with Stage IV or recurrent Stage III metastatic melanoma. Commencing on the date that principal payments commence, the Company will make consecutive monthly payments of principal and interest based upon a repayment schedule equal to (a) 36 months, if the Term Loans begin amortizing on October 1, 2015, or (b) 30 months, if the Term Loans begin amortizing on April 1, 2016. The Term Loans mature on September 1, 2018. At its option, the Company may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest), subject to a prepayment fee that is determined based on the date the loan is prepaid. The Company is also required to pay Lender a final payment fee equal to 8% of the Term Loan A and Term Loan B (if disbursed). The final payment fee will be amortized to interest expense throughout the life of the Term Loans using the effective interest rate method. The Company paid a facility fee in the amount of $100,000 in connection with Term Loan A.

Under the Loan and Security Agreement and a related mortgage, the Company granted to Lender a security interest in all of the Company’s real property and personal property now owned or hereafter acquired, excluding intellectual property, and certain other assets and exemptions. The Company also entered into a Mortgage and Absolute Assignment of Leases and Rents (the "Mortgage"). The Company also granted Lender a security interest in the shares of the Company’s subsidiaries. The Loan and Security Agreement restricts the ability of the Company to: (a) convey, lease, sell, transfer or otherwise dispose of any part of its business or property; and (b) incur any additional indebtedness. The Loan and Security Agreement provides for standard indemnification of Lender and contains representations, warranties and certain covenants of the Company. Upon the occurrence of an event of default by the Company under the Loan and Security Agreement, Lender will have customary acceleration, collection and foreclosure remedies. There are no financial covenants associated to the Loan and Security Agreement. As of March 31, 2015, the Company was in compliance with all covenants under the Loan and Security Agreement.

Estimated future principal payments, interest, and fees due under the Loan and Security Agreement, assuming the Company does not draw down on the Term B Loan, are as follows:



Years Ending December 31,	(in millions)
2015	$	2.1
2016	5.7
2017	5.7
2018	5.4
Total	$	18.9

During the three months ended March 31, 2015, the Company recognized $0.3 million of interest expense related to the Loan and Security Agreement.

Shareholders' Equity

3 Months Ended

Mar. 31, 2015

Shareholders’ Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Shareholders' Equity

Equity Issuances

In March 2014, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30.0 million worth of shares (up to a maximum of 5.7 million shares) of the Company’s common stock over the 24-month term. At the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price and other requirements are met. The purchase price for the shares of stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreement. As consideration for entering into the Purchase Agreement, we issued 150,000 shares of our common stock to Aspire Capital. During the three months ended March 31, 2015, the Company issued 2.2 million shares of common stock under the provisions of the Purchase Agreement with Aspire for gross proceeds of approximately $7.4 million. As of March 31, 2015, the remaining amount available to the Company under the Purchase Agreement was $11.7 million, subject to an issuance limit of 1.4 million shares.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2015:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2014	4,427,234		$	9.19	6.93	$	28.6	3,550,956		$	14.12	2.12	$	1.0

Changes during the period:
Granted	2,121,488		$	3.68				—		$	—
Exercised	—		$	—				—		$	—
Forfeited	(81,097	)	$	6.92				—		$	—
Expired	(96,092	)	$	7.18				(5,200	)	$	14.20
Outstanding at March 31, 2015	6,371,533		$	7.41	7.70	$	—	3,545,756		$	14.12	1.88	$	—
Vested at March 31, 2015 or expected to vest in the future	5,841,147		$	7.67	7.52	$	—	3,545,756		$	14.12	1.88	$	—
Vested at March 31, 2015	3,720,160		$	9.11	6.62	$	—	3,545,756		$	14.13	1.88	$	—

Restricted Stock

During the three months ended March 31, 2015 and 2014, the Company issued restricted stock for services as follows ($ in thousands, except share data):



	Three Months Ended March 31,
	2015		2014
Number of Restricted Stock Issued	818,004		329,698
Value of Restricted Stock Issued	$	2,955.8	$	2,511.7

The weighted average estimated fair value of restricted stock issued for services in the three months ended March 31, 2015 and 2014 was $3.61 and $7.62 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Share-Based Compensation (Notes)

3 Months Ended

Mar. 31, 2015

Share-based Compensation [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2015 and 2014 (in thousands):



	Three Months Ended March 31,
	2015		2014
Cost of goods sold	$	116.9	$	138.1
Research and development	422.7		476.8
Selling, general and administrative	3,176.1		3,278.7
Total share-based compensation expense	$	3,715.7	$	3,893.6

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at March 31, 2015 were as follows ($ in thousands):



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	7,226.2	$	7.5	$	213.9
Expected weighted-average period in years of compensation cost to be recognized	5.17		0.30		0.18

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2015 and 2014 were as follows ($ in thousands):



	Stock Options				Warrants
	Three Months Ended March 31,				Three Months Ended March 31,
	2015		2014		2015		2014
Total fair value of shares vested	$	2,706.2	$	1,927.4	$	6.8	$	8.7
Weighted average estimated fair value of shares granted	$	2.44	$	5.47	$	—	$	—

Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2015
Income Taxes [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes As of December 31, 2014, the Company had approximately $177.2 million of Federal net operating loss carryforwards (NOLs) available to offset future taxable income expiring from 2025 through 2033. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2032. In assessing the realizability of deferred tax assets, including the NOLs, the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time. Deferred tax liabilities were $18.2 million and $18.2 million as of March 31, 2015 and December 31, 2014, respectively, and relate to the taxable temporary differences on (i) the goodwill recognized in the PCT acquisition in 2011, (ii) the in-process R&D intangible asset recognized in the Amorcyte Acquisition in 2011, and (iii) the in-process R&D intangible asset recognized in the CSC Acquisition in 2014. The taxable temporary difference associated with the goodwill, which is tax deductible and will be amortized over 15 years, will continue to increase the deferred tax liability balance over the amortization period, with an associated charge to the tax provision in each period. The deferred tax liabilities will only reverse when these indefinite-lived assets are sold, impaired, or reclassified from an indefinite-lived asset to a finite-lived asset. As of March 31, 2015, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year. The Company's Federal tax returns are currently being audited for the years 2012 and 2013. For years prior to 2011 the federal statute of limitations is closed for assessing tax. The Company’s state tax returns remain open to examination for a period of 3 to 4 years from date of filing. The Company ceased doing business in China in 2012. After 2012, the Company had no foreign tax filing obligations. The returns filed for 2012 and prior are subject to examination for 5 years.

Commitments and Contingencies

3 Months Ended

Mar. 31, 2015

Commitments and Contingencies [Abstract]

Commitments and Contingencies [Text Block]

Commitments and Contingencies

Lease Commitments

The Company leases offices, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2018. In January 2014, the Company signed a new lease for a larger space at its New York office located at 420 Lexington Avenue, New York, NY 10170. This property is used as the Company's corporate headquarters. The new lease extends through 2018. In connection with the CSC Acquisition, the Company assumed a facility lease in Irvine, California, with a termination at the end of 2017. We recently signed an amendment expanding our office space in Irvine by 4,000 square feet, and extending the term through 2021. In accordance with the amendment, we plan to occupy the additional space by the second quarter of 2015.

We recently entered into an assignment agreement with an unaffiliated third party, effective February 19, 2015, for general office space located in Basking Ridge, New Jersey. The space is approximately 18,000 rentable square feet. Pursuant to the agreement, we are not obligated to make any payments for the space until January 2016.The base monthly rent during the period ending January 31, 2016 is currently $25,000 and the lease term ends July 31, 2020. In addition, there are two (2) five (5) year renewal options. In connection with the assumption of the lease, the third party (a) conveyed its rights in various scheduled furniture and equipment and (b) paid the Company approximately $580,000 which will offset the future rental payments to be paid by NeoStem until mid 2016. The amount paid to the Company included a security deposit of approximately $115,000.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of March 31, 2015 are as follows (in thousands):



Years ended	Operating Leases
2015	$	1,439.3
2016	2,039.3
2017	1,841.0
2018	1,023.8
2019 and thereafter	1,909.2
Total minimum lease payments	$	8,252.6

Expense incurred under operating leases was approximately $0.4 million and 0.2 million for the three months ended March 31, 2015 and 2014, respectively.

Contingencies

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results.

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2015
Subsequent Events [Abstract]
Commitments and Contingencies [Text Block]	Subsequent Events Common Stock Issuances Pursuant to the Purchase Agreement with Aspire (see Note 12), from April 1, 2015 through May 4, 2015, Aspire has purchased 0.8 million shares of the Company's common stock for an aggregate consideration of approximately $2.0 million. 2015 Aspire Agreement On May 4, 2015, the Company entered into a Common Stock Purchase Agreement with Aspire, whereby Aspire is committed to purchase up to an aggregate of $30 million of shares of NeoStem common stock over a 24-month term. Long-Term Debt: Interest-Only Period Extension On April 29, 2015, the Company announced that the first patient in the Intus Study has been randomized. In accordance with the Company's Loan and Security Agreement with Oxford (see Note 10), based on the initiation of this study, the interest-only payment period on Term Loan A has been extended to April 1, 2016.

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2015

Summary of Significant Accounting Policies [Abstract]

Schedule of Cash and Cash Equivalents [Table Text Block]

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of 90 days or less when purchased.

Marketable Securities, Policy [Policy Text Block]

Marketable Securities

Receivables, Policy [Policy Text Block]

Accounts Receivable

Inventory Disclosure [Text Block]

Goodwill and Intangible Assets, Policy [Policy Text Block]

Goodwill and Indefinite-Lived Intangible Assets

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.

We recognize revenues when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Pronouncement

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References + Details

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References + Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

The Business (Tables)

3 Months Ended

Mar. 31, 2015

The Business [Abstract]

Subsidiary [Table Text Block]



Entity	Percentage of Ownership	Location
NeoStem, Inc.	100%	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	96.6%	United States of America
PCT Allendale, LLC	100%	United States of America
NeoStem Oncology, LLC	100%	United States of America

Acquisition (Tables)

3 Months Ended

Mar. 31, 2015

Business Combinations [Abstract]

Business Acquisition, Pro Forma Information [Table Text Block]



	Three Months Ended March 31, 2014
	(As Reported)			(Proforma)
Revenues	$	4,056		$	4,272
Net loss	$	(13,830	)	$	(15,523	)
Net loss attributable to NeoStem	$	(13,682	)	$	(15,375	)
Net loss per share attributable to NeoStem	$	(0.49	)	$	(0.46	)

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The preliminary fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):



Cash and cash equivalents	$	51
Accounts receivable trade, net	45
Prepaids and other current assets	19
Property, plant and equipment, net	1,041
Other assets	201
Goodwill	14,092
In-Process R&D	34,290
Accounts payable	(333		)
Accrued liabilities	(2,014		)
Deferred tax liability	(13,901		)
Total	$	33,491

Available-for-Sale-Securities (Tables)

3 Months Ended

Mar. 31, 2015

Available-for-sale Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	March 31, 2015
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Money market funds	$	14,513.1	$	—	$	—	$	14,513.1
Total	$	14,513.1	$	—	$	—	$	14,513.1

Marketable Securities [Table Text Block]



	March 31, 2015
Cash and cash equivalents	$	14,513.1
Marketable securities	—
Total	$	14,513.1

Investments Classified by Contractual Maturity Date [Table Text Block]

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	March 31, 2015
	Amortized Cost		Estimated Fair Value
Less than one year	$	14,513.1	$	14,513.1
Greater than one year	—		—
Total	$	14,513.1	$	14,513.1

Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2015

Loss Per Share [Abstract]

ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]

At March 31, 2015 and 2014, the Company excluded the following potentially dilutive securities:



	March 31,
	2015	2014
Stock Options	6,371,533	3,912,697
Warrants	3,545,756	4,491,028
Restricted Shares	218,229	175,731

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2015

Fair Value Measurements [Abstract]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]

•



	March 31, 2015								December 31, 2014
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	—	$	—	$	—	$	—	$	7,080.0	$	—	$	7,080.0
	$	—	$	—	$	—	$	—	$	—	$	7,080.0	$	—	$	7,080.0

Liabilities:
Contingent consideration	$	—	$	—	$	18,810.0	$	18,810.0	$	—	$	—	$	18,260.0	$	18,260.0
	$	—	$	—	$	18,810.0	$	18,810.0	$	—	$	—	$	18,260.0	$	18,260.0

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three months ended March 31, 2015 by type of instrument (in thousands):



	Three Months Ended
	March 31, 2015
	Contingent Consideration		Total
Beginning liability balance	$	18,260.0	$	18,260.0
Change in fair value recorded in operations	550.0		550.0
Ending liability balance	$	18,810.0	$	18,810.0

Goodwill and Other Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2015

Goodwill and Other Intangible Assets [Abstract]

Schedule of Goodwill [Table Text Block]

The Company's goodwill was $25.2 million as of March 31, 2015 and December 31, 2014.

Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]

The Company's intangible assets and related accumulated amortization as of March 31, 2015 and December 31, 2014 consisted of the following (in thousands):



		March 31, 2015							December 31, 2014
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(420.1	)	$	579.9	$	1,000.0	$	(395.1	)	$	604.9
Manufacturing technology	10 years	3,900.0		(1,638.4		)	2,261.6		3,900.0		(1,540.9		)	2,359.1
Tradename	10 years	800.0		(336.1		)	463.9		800.0		(316.1		)	483.9
In process R&D	Indefinite	43,690.0		—			43,690.0		43,690.0		—			43,690.0
Patent rights	19 years	669.0		(255.3		)	413.7		669.0		(246.5		)	422.5
Total Intangible Assets		$	50,059.0	$	(2,649.9	)	$	47,409.1	$	50,059.0	$	(2,498.6	)	$	47,560.4

Schedule of Amortization Expense [Table Text Block]

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Three Months Ended March 31,
	2015		2014
Cost of revenue	$	79.2	$	79.2
Research and development	27.1		27.1
Selling, general and administrative	45.0		45.0
Total	$	151.3	$	151.3

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2015	$	453.9
2016	605.2
2017	605.2
2018	605.2
2019	605.2
Thereafter	44,534.4
Total	$	47,409.1

Accrued Liabilities Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2015

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities as of March 31, 2015 and December 31, 2014 were as follows (in thousands):



	March 31, 2015		December 31, 2014
Salaries, employee benefits and related taxes	$	3,335.9	$	2,807.2
Professional fees	463.6		495.4
Other	1,924.3		1,020.3
Total	$	5,723.8	$	4,322.9

Debt Long term debt (Tables)

3 Months Ended

Mar. 31, 2015

Long-term Debt, Unclassified [Abstract]

Schedule of Maturities of Long-term Debt [Table Text Block]

Estimated future principal payments, interest, and fees due under the Loan and Security Agreement, assuming the Company does not draw down on the Term B Loan, are as follows:



Years Ending December 31,	(in millions)
2015	$	2.1
2016	5.7
2017	5.7
2018	5.4
Total	$	18.9

Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2015

Shareholders’ Equity [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity for stock options and warrants for the three months ended March 31, 2015:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2014	4,427,234		$	9.19	6.93	$	28.6	3,550,956		$	14.12	2.12	$	1.0

Changes during the period:
Granted	2,121,488		$	3.68				—		$	—
Exercised	—		$	—				—		$	—
Forfeited	(81,097	)	$	6.92				—		$	—
Expired	(96,092	)	$	7.18				(5,200	)	$	14.20
Outstanding at March 31, 2015	6,371,533		$	7.41	7.70	$	—	3,545,756		$	14.12	1.88	$	—
Vested at March 31, 2015 or expected to vest in the future	5,841,147		$	7.67	7.52	$	—	3,545,756		$	14.12	1.88	$	—
Vested at March 31, 2015	3,720,160		$	9.11	6.62	$	—	3,545,756		$	14.13	1.88	$	—

Restricted Stock [Table Text Block]

During the three months ended March 31, 2015 and 2014, the Company issued restricted stock for services as follows ($ in thousands, except share data):



	Three Months Ended March 31,
	2015		2014
Number of Restricted Stock Issued	818,004		329,698
Value of Restricted Stock Issued	$	2,955.8	$	2,511.7

Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2015

Share-based Compensation [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table summarizes the components of share-based compensation expense for the three months ended March 31, 2015 and 2014 (in thousands):



	Three Months Ended March 31,
	2015		2014
Cost of goods sold	$	116.9	$	138.1
Research and development	422.7		476.8
Selling, general and administrative	3,176.1		3,278.7
Total share-based compensation expense	$	3,715.7	$	3,893.6

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	7,226.2	$	7.5	$	213.9
Expected weighted-average period in years of compensation cost to be recognized	5.17		0.30		0.18

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the three months ended March 31, 2015 and 2014 were as follows ($ in thousands):



	Stock Options				Warrants
	Three Months Ended March 31,				Three Months Ended March 31,
	2015		2014		2015		2014
Total fair value of shares vested	$	2,706.2	$	1,927.4	$	6.8	$	8.7
Weighted average estimated fair value of shares granted	$	2.44	$	5.47	$	—	$	—

Valuation Assumptions

Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2015

Commitments and Contingencies [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of March 31, 2015 are as follows (in thousands):



Years ended	Operating Leases
2015	$	1,439.3
2016	2,039.3
2017	1,841.0
2018	1,023.8
2019 and thereafter	1,909.2
Total minimum lease payments	$	8,252.6

The Business (Details) - USD ($)	3 Months Ended
The Business (Details) - USD ($)	Mar. 31, 2015	Mar. 31, 2014
The Company [Line Items]
Subsidiary, Ownership Interest by Parent	96.60%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	3.40%
Change in Ownership in Subsidiary	$ 0	$ 0
Noncontrolling Interest [Member]
The Company [Line Items]
Change in Ownership in Subsidiary	$ 50,537	$ 86,617
NeoStem, Inc. [Member]
The Company [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%

The Business Principal of consolidation (Details)	Mar. 31, 2015
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	96.60%
NeoStem, Inc. [Member]
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Therapies, Inc [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Stem Cell Technologies, Inc [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Amorcyte, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Progenitor Cell Therapy, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Family Storage, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
PCT Allendale, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Oncology [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Summary of Significant Accounting Policies [Abstract]
Clinical Services Reimbursement	$ 0.5	$ 0.7

Acquisition (Details) - USD ($)	3 Months Ended
Acquisition (Details) - USD ($)	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	May 08, 2014
Business Acquisition [Line Items]
Change in acquisition-related contingent consideration	$ 550,000	$ 190,000
Revenues	3,172,279	4,055,575
Net loss	$ (19,231,488)	(13,830,084)
Common Stock, Shares, Issued	39,423,911		36,783,857	5,329,593
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				$ 90,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net				19,400,000
Acquisition-related contingent consideration	$ 18,810,000		$ 18,260,000	11,900,000
Business Acquisition, Transaction Costs				33,500,000
Cash and cash equivalents				51,000
Accounts receivable, net of allowance for doubtful accounts of $390,118 and $391,829 at March 31, 2014 and December 31, 2013, respectively				45,000
Prepaid expenses and other current assets				19,000
Property, plant and equipment, net				1,041,000
Other assets				201,000
Goodwill	25,209,336		$ 25,209,336	14,092,000
Equity Issued in Business Combination, Fair Value Disclosure				21,600,000
Intangible assets, net				34,290,000
Accounts Payable, Current				(333,000)
Accrued Liabilities, Current				(2,014,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent				(13,901,000)
Deferred Tax Liabilities, Net, Noncurrent	$ (46,633)	$ (47,409)
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	$ (0.51)	$ (0.49)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net				$ 33,491,000
NeoStem Oncology [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue		$ 4,272,000
Business Acquisition, Pro Forma Net Income (Loss)		(15,523,000)
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		$ (15,375,000)
Business Acquisition, Pro Forma Earnings Per Share, Diluted		$ (0.46)
NeoStem, Inc. [Member]
Business Acquisition [Line Items]
Revenues		$ 4,056,000
Net loss		(13,830,000)
Net Income (Loss) Attributable to Parent		$ (13,682,000)
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders		$ (0.49)

Available-for-Sale-Securities Schedule of Available-for-sale Securites Reconciliation (Details)	Mar. 31, 2015 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	$ 14,513,100
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0
Certificates of Deposit, at Carrying Value	14,513,100
Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	14,513,100
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0
Certificates of Deposit, at Carrying Value	$ 14,513,100

Available-for-Sale-Securities Classification of the available-for-sale securities (Details)	Mar. 31, 2015 USD ($)
Available-for-sale Securities [Abstract]
Cash	$ 14,513,100
Marketable securities	0
Total	$ 14,513,100

Available-for-Sale-Securities Available-for-sale Securities by Contractual Maturity (Details)	Mar. 31, 2015 USD ($)
Available-for-sale Securities [Abstract]
Less than one year, Amortized Cost	$ 14,513,100
Less than one year, Fair Value	14,513,100
Amortized Cost	14,513,100
Estimated Fair Value	$ 14,513,100

Deferred Costs (Details) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Schedule of Inventory [Line Items]
Deferred costs	$ 3,621,351	$ 2,566,989
Multiple Stage Contracts [Member]
Schedule of Inventory [Line Items]
Deferred Revenue	$ 5,100,000	$ 3,900,000

Loss Per Share (Details) - shares	3 Months Ended
Loss Per Share (Details) - shares	Mar. 31, 2015	Mar. 31, 2014
Warrants
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	3,545,756	4,491,028
Stock Options [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	6,371,533	3,912,697
Restricted Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	218,229	175,731

Fair Value Measurements Fair value hierarchy the Company’s financial assets and liabilities (Details) - USD ($)	Mar. 31, 2015	Dec. 31, 2014	May 08, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	$ 18,810,000	$ 18,260,000	$ 11,900,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			$ 90,000,000
Accrued Liabilities and Other Liabilities	18,810,000	18,260,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	13,200,000	12,800,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	0	0
Accrued Liabilities and Other Liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	0	0
Accrued Liabilities and Other Liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	18,810,000	18,260,000
Accrued Liabilities and Other Liabilities	18,810,000	18,260,000
Contingent Consideration Classified as Equity [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	18,810,000	18,260,000
Amorcyte, LLC [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	5,600,000	5,500,000
Contingent Consideration Classified as Equity [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	$ 18,810,000	$ 18,260,000

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	May 08, 2014	Oct. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	$ 0		$ 7,080,000
Percentage of Net Sales					10.00%
Percentage of license cost					30.00%
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition-related contingent consideration	18,810,000		18,260,000	$ 11,900,000
Accrued Liabilities and Other Liabilities	18,810,000		18,260,000
Change in acquisition-related contingent consideration	550,000	$ 190,000
Fair Value, Option, Changes in Fair Value, Gain (Loss)	550,000
Contingent Consideration Classified as Equity [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition-related contingent consideration	18,810,000		18,260,000
Change in acquisition-related contingent consideration	550,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0		0
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Accrued Liabilities and Other Liabilities	0		0
Contingent Consideration Classified as Equity, Fair Value Disclosure	0		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0		7,080,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Accrued Liabilities and Other Liabilities	0		0
Contingent Consideration Classified as Equity, Fair Value Disclosure	0		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0		0
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Accrued Liabilities and Other Liabilities	18,810,000		18,260,000
Contingent Consideration Classified as Equity, Fair Value Disclosure	$ 18,810,000		$ 18,260,000

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) - USD ($)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Goodwill [Roll Forward]
Goodwill	$ 25,209,336
Finite-Lived Intangible Assets, Gross	50,059,000	$ 50,059,000
Finite-Lived Intangible Assets, Accumulated Amortization	(2,649,900)	(2,498,600)
Finite-Lived Intangible Assets, Future Amortization Expense	47,409,100	47,560,400
Customer Lists [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	1,000,000	1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(420,100)	(395,100)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 579,900	604,900
Finite-Lived Intangible Assets, Useful Life	10 years
Manufacturing Technology [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	$ 3,900,000	3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	(1,638,400)	(1,540,900)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 2,261,600	2,359,100
Finite-Lived Intangible Assets, Useful Life	10 years
Trade Names [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	$ 800,000	800,000
Finite-Lived Intangible Assets, Accumulated Amortization	(336,100)	(316,100)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 463,900	483,900
Finite-Lived Intangible Assets, Useful Life	10 years
In Process R and D [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	$ 43,690,000	43,690,000
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Finite-Lived Intangible Assets, Future Amortization Expense	43,690,000	43,690,000
VSEL Patent Rights [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	669,000	669,000
Finite-Lived Intangible Assets, Accumulated Amortization	(255,300)	(246,500)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 413,700	$ 422,500
Finite-Lived Intangible Assets, Useful Life	19 years

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 151,300	$ 151,300
Cost of revenue
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	79,200	79,200
Research and development
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	27,100	27,100
Selling, general and administrative
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 45,000	$ 45,000

Goodwill and Other Intangible Assets Goodwill (Details) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Goodwill [Abstract]
Goodwill	$ 25,200,000
Future Amortization Expense, Year One	453,900
Future Amortization Expense, Year Two	605,200
Future Amortization Expense, Year Three	605,200
Future Amortization Expense, Year Four	605,200
Future, Amortization Expense, Year Five	605,200
Thereafter	44,534,400
Finite-Lived Intangible Assets, Future Amortization Expense	$ 47,409,100	$ 47,560,400

Accrued Liabilities Accrued Liabilities (Details) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes	$ 3,335,900	$ 2,807,200
Professional fees	463,600	495,400
Other	1,924,300	1,020,300
Accrued Liabilities	$ 5,723,800	$ 4,322,900

Debt (Details) - USD ($) $ in Millions	3 Months Ended
Debt (Details) - USD ($) $ in Millions	Mar. 31, 2015	Dec. 31, 2014	Sep. 26, 2014
Debt Instrument [Line Items]
Notes Payable	$ 1.7	$ 1.6
Mortgages payable			$ 20.0
Debt Instrument, Periodic Payment	10.0
Proceeds from Issuance of Debt	11.7
Debt Issuance Cost	(0.1)
Mortgage Loans on Real Estate, Carrying Amount of Mortgages	3.1
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Two	2.1
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Three	5.7
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Four	5.7
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Five	5.4
Long-term Debt	18.9
Interest expense	$ 0.3
Impaired Long-Lived Assets Held and Used, Asset Name [Domain]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Interest	8.00%
Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	8.50%
NeoStem, Inc. [Member] \| Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Period of Loan	36 months
Debt Instrument, Payment Terms	30 months
License Agreement Terms [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross			$ 5.0

Shareholders' Equity Equity Issuances (Details) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	May 08, 2014
Class of Stock [Line Items]
Common Stock, Shares, Issued	39,423,911	39,423,911		36,783,857	5,329,593
Net proceeds from issuance of common stock		$ 7,411,828	$ 5,630,625
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Term of agreement in months	24 months
Discount Applied To Weighted Average Price			5.00%
Purchase Commitment, Remaining Minimum Amount Committed	$ 11,700,000	$ 11,700,000
Stock Issued During Period, Shares, Other		5,687,942
Stock Issued During Period, Shares, New Issues		2,200,000
Net proceeds from issuance of common stock		$ 7,400,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Common Stock, Shares, Issued			150,000
Purchase Commitment, Remaining Minimum Amount Committed			$ 30,000,000
Common Stock, Capital Shares Reserved for Future Issuance			1,400,000

Shareholders' Equity Stock options and warrants (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2015 USD ($) $ / shares $ / warrant shares	Dec. 31, 2014 USD ($) $ / shares $ / warrant shares
Stock Options and Warrants [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value \| $	$ 0	$ 28,600
Common Stock Warrants, Shares	3,545,756	3,550,956
Weighted Average Exercise Price, Warrants Outstanding \| $ / warrant	14.12	14.12
Weighted Average Remaining Contractual Term warrant outstanding	1 year 10 months 17 days	2 years 1 month 13 days
Aggregate Intrinsic Value, Warrants Outstanding \| $	$ 0	$ 1,000
Warrants Granted	0
Warrants Canceled	5,200
Weighted Average Exercise Price, Warrants Granted \| $ / shares	$ 0.00
Warrants Exercised	0
Weighted Average Exercise Price, Warrants Exercised \| $ / shares	$ 0.00
Warrants Expired	0
Weighted Average Exercise Price, Warrants Expired \| $ / shares	$ 0.00
Weighted Average Exercise Price, Warrants Canceled \| $ / shares	$ 14.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value \| $	$ 0
shares, vested and expected to vest	3,545,756
Weighted Average Exercise Price, Warrants vested & expected to vest \| $ / warrant	14.12
Aggregate Intrinsic Value, Warrants vested and expected to vest \| $	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	3,545,756
Weighted Average Exercise Price, Warrants Exercisable \| $ / warrant	14.13
weighted Average Remaining Contractual Term, warrants vested	1 year 10 months 17 days
Aggregate Intrinsic Value, Warrants vested \| $	$ 0
US Equity Plan [Member]
Stock Options and Warrants [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,371,533	4,427,234
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 7.41	$ 9.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 8 months 12 days	6 years 11 months 5 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	2,121,488
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 3.68
Stock Options Exercised	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 0.00
Stock Options Expired	(81,097)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price \| $ / shares	$ 6.92
Stock Options Forfeited	(96,092)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price \| $ / shares	$ 7.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	5,841,147
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 7.67
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	7 years 6 months 7 days
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	1 year 10 months 17 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	3,720,160
Weighted average estimated fair value of shares granted \| $ / shares	$ 9.11
Options, Vested, weighted Average Remaining Contractual Term	6 years 7 months 13 days

Shareholders' Equity Restricted Stock (Details) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	818,004	329,698
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 2,955,800	$ 2,511,700
weighted average estimated fair value of restricted stock	$ 3.61	$ 7.62

Share-Based Compensation Share-Based Compensation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 3,715,700	$ 3,893,600
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 7,226,200
Expected weighted-average period in years of compensation cost to be recognized	5 years 2 months 1 day
Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 7,500
Expected weighted-average period in years of compensation cost to be recognized	3 months 18 days
Total fair value of shares vested	$ 6,800	8,700
Weighted average estimated fair value of shares granted	$ 0.00		$ 0.00
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average estimated fair value of shares granted	$ 2.44		$ 5.47
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 213,900
Expected weighted-average period in years of compensation cost to be recognized	2 months 5 days
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 116,900	138,100
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	422,700	476,800
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	3,176,100	3,278,700
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested	$ 2,706,200	$ 1,927,400

Income Taxes Net Operating Loss Carry Forward (Details) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards		$ 177,200,000
Deferred Tax Liabilities, Net, Noncurrent	$ 18,222,823	$ 18,176,190

Commitments and Contingencies (Details) ft² in Thousands		3 Months Ended
Commitments and Contingencies (Details) ft² in Thousands	Feb. 19, 2015 USD ($) ft² yr	Mar. 31, 2015 USD ($) ft²	Mar. 31, 2014 USD ($)
Operating Leases, Future Minimum Payments Due [Abstract]
2015		$ 1,439,300
2016		2,039,300
2017		1,841,000
2018		1,023,800
2019 and thereafter		1,909,200
Total minimum lease payments		8,252,600
Operating lease expense		$ 400,000	$ 200,000
CALIFORNIA
Operating Leased Assets [Line Items]
Operating lease, additional space rented \| ft²		4
NEW JERSEY
Operating Leased Assets [Line Items]
Operating lease, rentable space \| ft²	18
Operating leases, monthly rental payments	$ 25,000
Operating leases, number of renewal terms \| yr	2
Lessee leasing arrangements, operating leases, renewal term	5 years
Proceeds from lease assignment	$ 580,000
Security deposit liability		$ 115,000

Subsequent Events (Details) - USD ($)		3 Months Ended		4 Months Ended
Subsequent Events (Details) - USD ($)	May 04, 2015	Mar. 31, 2015	Mar. 31, 2014	May 05, 2015	May 01, 2015	Dec. 31, 2014	Sep. 26, 2014	May 08, 2014
Subsequent Event [Line Items]
Common Stock, Shares, Issued		39,423,911				36,783,857		5,329,593
Net proceeds from issuance of common stock		$ 7,411,828	$ 5,630,625
Aspire Capital Purchase Agreement [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued			150,000
Purchase Commitment, Remaining Minimum Amount Committed			$ 30,000,000
Long-term Debt, Gross							$ 15,000,000
Aspire Capital Purchase Agreement [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued					800,000
Net proceeds from issuance of common stock				$ 2,000,000
Term of agreement in months	24 months
Purchase Commitment, Remaining Minimum Amount Committed					$ 30,000,000